Person
Presta, Marco
|
|
Biography and Research Interest
Marco PRESTA, born on June 21, 1954, Italy; Italian; 1977: PhD in Biological Sciences, University of Milan, Italy; 1984-86: Research Fellow, School of Medicine, N.Y.U. Medical Center, N.Y., U.S.A; 1984-87: Research Assistant Professor, Univ. Brescia, Italy; 1987-2000: Associate Professor; 2000-today: Full Professor in General Pathology, Univ. Brescia, Italy.
Scientific Societies: American Society for Cell Biology, New York Academy of Sciences, American Association Cancer Research.
Fields of Research: 1975-77: Quantification of ischemic damage in miocardium and skeletric muscle; 1977-79: Hepatic tumor promoters and liver growth; 1980: Human embryonic hemoglobins and globin chains in leukemic cells lines; 1980-84: Genotoxic and oncogenic activity of beta-adrenoreceptor blocking agents; 1984-present: Tumor angiogenesis, purification and characterization of human angiogenic factors (FGFs), identification of their functional domains and interaction with sulfated glycosaminoglycans, FGF/receptor interaction and signal transduction, FGF overexpression in tumor and endothelial cells.
Editorial Board: Endothelium, Angiogenesis.
Journal Peer Reviewer: Arteriosclerosis, Thrombosis, and Vascular Biology, Cell Growth & Differentiation, EMBO Journal, European Journal of Cancer, European Journal of Clinical Investigation, Growth Factors, International Journal of Cancer, International Journal of Clinical and Laboratory Research, Regulatory Peptides, Journal of Cell Biology, Journal of Cellular Physiology, Journal of Endocrinology, Journal of Leukocyte Biology.
Granting Agency Reviewer: The Wellcome Trust, London;The Flemish Foundation for Scientific Research (FWO), Brussels;International Human Frontier Science Program, Strasbourg;The Israel Science Foundation, Jerusalem;NATO Scientific Affairs Division (Collaborative Research Grants), Brussels;Istituto Superiore di Sanità (AIDS Projects)and CNR (Target Project Biotechnology), Italy
Scientific Societies: American Society for Cell Biology, New York Academy of Sciences, American Association Cancer Research.
Fields of Research: 1975-77: Quantification of ischemic damage in miocardium and skeletric muscle; 1977-79: Hepatic tumor promoters and liver growth; 1980: Human embryonic hemoglobins and globin chains in leukemic cells lines; 1980-84: Genotoxic and oncogenic activity of beta-adrenoreceptor blocking agents; 1984-present: Tumor angiogenesis, purification and characterization of human angiogenic factors (FGFs), identification of their functional domains and interaction with sulfated glycosaminoglycans, FGF/receptor interaction and signal transduction, FGF overexpression in tumor and endothelial cells.
Editorial Board: Endothelium, Angiogenesis.
Journal Peer Reviewer: Arteriosclerosis, Thrombosis, and Vascular Biology, Cell Growth & Differentiation, EMBO Journal, European Journal of Cancer, European Journal of Clinical Investigation, Growth Factors, International Journal of Cancer, International Journal of Clinical and Laboratory Research, Regulatory Peptides, Journal of Cell Biology, Journal of Cellular Physiology, Journal of Endocrinology, Journal of Leukocyte Biology.
Granting Agency Reviewer: The Wellcome Trust, London;The Flemish Foundation for Scientific Research (FWO), Brussels;International Human Frontier Science Program, Strasbourg;The Israel Science Foundation, Jerusalem;NATO Scientific Affairs Division (Collaborative Research Grants), Brussels;Istituto Superiore di Sanità (AIDS Projects)and CNR (Target Project Biotechnology), Italy
Non-Zebrafish Publications
1. Andres G, Leali D, Mitola S, et al. A Pro-inflammatory Signature Mediates FGF2-induced Angiogenesis. J Cell Mol Med 2008.2. Stabile H, Mitola S, Moroni E, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 2007;109:1834-40.
3. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007;13:2025-44.
4. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007;11:723-38.
5. Leali D, Moroni E, Bussolino F, Presta M. Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem 2007;282:19676-84.
6. Rusnati M, Presta M. Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium 2006;13:93-111.
7. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006;1:85-91.
8. Mitola S, Belleri M, Urbinati C, et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006;176:12-5.
9. Camozzi M, Rusnati M, Bugatti A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006;281:22605-13.
10. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78.
11. Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005;25:1837-42.
12. Riboldi E, Musso T, Moroni E, et al. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol 2005;175:2788-92.
13. Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9.
14. Belleri M, Ribatti D, Nicoli S, et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol 2005;67:1451-9.
15. Casu B, Guerrini M, Guglieri S, et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 2004;47:838-48.